Literature DB >> 8617580

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.

H S Puc1, D F Bajorin, G J Bosl, A Amsterdam, R J Motzer.   

Abstract

Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8617580     DOI： 10.1007/bf00872866

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

1.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

Authors:  C Jaxel; K W Kohn; M C Wani; M E Wall; Y Pommier
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

2.  Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

Authors:  L Saltz; M Sirott; C Young; W Tong; D Niedzwiecki; Y Tzy-Jyun; Y Tao; B Trochanowski; P Wright; K Barbosa
Journal:  J Natl Cancer Inst       Date:  1993-09-15       Impact factor: 13.506

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.

Authors:  T C Chou; R J Motzer; Y Tong; G J Bosl
Journal:  J Natl Cancer Inst       Date:  1994-10-19       Impact factor: 13.506

Review 5.  The current status of camptothecin analogues as antitumor agents.

Authors:  W J Slichenmyer; E K Rowinsky; R C Donehower; S H Kaufmann
Journal:  J Natl Cancer Inst       Date:  1993-02-17       Impact factor: 13.506
  5 in total
  2 in total

Review 1.  Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

Authors:  C J Gerrits; M J de Jonge; J H Schellens; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

Authors:  C Kollmannsberger; O Rick; H Klaproth; T Kubin; H G Sayer; M Hentrich; M Welslau; F Mayer; M Kuczyk; C Spott; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.